Stryker Corporation (NYSE:SYK) Shares Bought by CoreFirst Bank & Trust

CoreFirst Bank & Trust lifted its stake in shares of Stryker Corporation (NYSE:SYK) by 18.5% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 806 shares of the medical technology company’s stock after buying an additional 126 shares during the quarter. CoreFirst Bank & Trust’s holdings in Stryker were worth $300,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in SYK. Capital A Wealth Management LLC bought a new stake in shares of Stryker in the 4th quarter valued at approximately $26,000. Rakuten Securities Inc. grew its position in shares of Stryker by 618.2% during the 4th quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock valued at $28,000 after buying an additional 68 shares during the last quarter. Goodman Advisory Group LLC bought a new stake in shares of Stryker during the 1st quarter valued at about $32,000. City Holding Co. raised its position in shares of Stryker by 528.6% during the 1st quarter. City Holding Co. now owns 88 shares of the medical technology company’s stock worth $33,000 after purchasing an additional 74 shares during the period. Finally, VSM Wealth Advisory LLC bought a new position in Stryker during the 4th quarter worth $36,000. Institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 200,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the completion of the sale, the director directly owned 3,417,326 shares in the company, valued at approximately $1,288,195,208.96. This trade represents a 5.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 5.90% of the stock is owned by corporate insiders.

Stryker Stock Up 0.0%

SYK stock opened at $392.00 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.64 and a quick ratio of 1.00. The firm has a market capitalization of $149.62 billion, a P/E ratio of 52.97, a P/E/G ratio of 2.98 and a beta of 0.91. Stryker Corporation has a 52-week low of $314.93 and a 52-week high of $406.19. The company’s 50 day simple moving average is $382.92 and its 200-day simple moving average is $376.25.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.73 by $0.11. The company had revenue of $5.87 billion for the quarter, compared to the consensus estimate of $5.68 billion. Stryker had a net margin of 12.31% and a return on equity of 23.74%. The company’s revenue was up 11.9% on a year-over-year basis. During the same period in the previous year, the business earned $2.50 EPS. As a group, equities research analysts anticipate that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be paid a dividend of $0.84 per share. The ex-dividend date is Monday, June 30th. This represents a $3.36 annualized dividend and a yield of 0.86%. Stryker’s dividend payout ratio (DPR) is presently 45.41%.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Truist Financial upped their price target on shares of Stryker from $390.00 to $400.00 and gave the stock a “hold” rating in a research report on Monday, May 5th. JMP Securities reissued a “market perform” rating on shares of Stryker in a report on Monday, May 5th. Roth Mkm upped their price objective on shares of Stryker from $405.00 to $456.00 and gave the stock a “buy” rating in a report on Friday, May 2nd. Needham & Company LLC reissued a “buy” rating and set a $442.00 target price on shares of Stryker in a research note on Friday, March 21st. Finally, Wall Street Zen lowered Stryker from a “buy” rating to a “hold” rating in a research note on Friday, June 27th. Five research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $427.30.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.